Clinical trial
Etanercept for Wegener's Granulomatosis
NCT00005007 · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH · Completed
Key facts
| NCT number | NCT00005007 |
|---|---|
| Title | Etanercept for Wegener's Granulomatosis |
| Official title | Wegener's Granulomatosis Etanercept Trial (WGET) |
| Lead sponsor | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH |
| Collaborators | FDA Office of Orphan Products Development U.S. Fed |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Wegener's Granulomatosis |
| Intervention type | Drug |
| Interventions | Etanercept |
| Enrollment | 181 |
| Start date | Jun 1, 2000 |
| Primary completion | Mar 1, 2003 |
| Completion | Mar 1, 2003 |
| First posted | Mar 27, 2000 |
| Last update posted | Dec 28, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: